<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03753074</url>
  </required_header>
  <id_info>
    <org_study_id>IN-KR-320-5358</org_study_id>
    <nct_id>NCT03753074</nct_id>
  </id_info>
  <brief_title>Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines</brief_title>
  <acronym>ATTENTION</acronym>
  <official_title>A Multicenter, Open-label, Randomized Controlled Trial to Investigate the Effectiveness of Tenofovir Alafenamide in Reducing Clinical Events in Chronic Hepatitis B Patients Beyond Treatment Indications by Current Guidelines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Young-Suk Lim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with Tenofovir Alafenamide(TAF) in Chronic Hepatitis B (CHB) patients classified as
      beyond treatment indication of current international guidelines (e.g. aged more than 40 years
      old and 4 ≤ log HBV-DNA IU/mL &lt; 8) is expected to bring improvement in long-term clinical
      outcomes. This expected result may expand the treatment indications in patients with CHB
      based on age and HBV-DNA in contrast to current international guidelines of CHB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study objectives: To investigate whether TAF treatment reduce clinical events (HCC, death,
      liver decompensation, portal hypertensive complications, and liver transplantation) in CHB
      patients beyond treatment indications by current guidelines

      Study procedure: 780 subjects will be randomized in a 1:1 ratio (A:B) either to receive TAF
      25 mg QD or to receive best supportive care after stratification according to the HBeAg
      status. The duration of maintaining both arms is 4 years. During treatment period, among
      treatment arm B, subjects who are indicated for antiviral treatment by AASLD 2018 Guidelines
      of CHB (ALT 70≥ for male, 50≥ for female) will be treated with TAF.

        -  Treatment Arm A: 390 subjects administered TAF 25 mg once daily

        -  Treatment Arm B: 390 subjects received best supportive care

      The primary analysis will occur at Year 4 with the primary endpoint being cumulative
      incidence rate of clinical events
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative rate of patients with clinical events</measure>
    <time_frame>At year4</time_frame>
    <description>Cumulative rate of patients with clinical events (death, liver transplantation, liver decompensation, portal hypertensive complications, and HCC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative rate of patients with clinical events</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative rate of patients with clinical events (death, liver transplantation, liver decompensation, portal hypertensive complications, and HCC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of HCC</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative incidence rate of HCC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of liver transplantation</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative incidence rate of liver transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of liver decompensation</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative incidence rate of liver decompensation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of portal hypertensive complications</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative incidence rate of portal hypertensive complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of receiving nucleos(t)ide analogue by meeting reimbursement criteria of treatment among Treatment ARM B subjects</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Rate of receiving nucleos(t)ide analogue by meeting reimbursement criteria of treatment among Treatment ARM B subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic response defined as HBV DNA less than 15 IU/mL</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Virologic response defined as HBV DNA less than 15 IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ALT normalization</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Rate of ALT normalization if baseline ALT is elevated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of HBeAg seroclearance and seroconversion</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Rate of HBeAg seroclearance and seroconversion among HBeAg-positive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of fibroscan</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Change of fibroscan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of APRI index</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Change of APRI index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of FIB-4</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Change of FIB-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of HCC among HBeAg-positive patients</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative incidence rate of HCC among HBeAg-positive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause-mortality among HBeAg-positive patients</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>All cause-mortality among HBeAg-positive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of liver transplantation among HBeAg-positive patients</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative incidence rate of liver transplantation among HBeAg-positive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of liver decompensation among HBeAg-positive patients</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative incidence rate of liver decompensation among HBeAg-positive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of portal hypertensive complications among HBeAg-positive patients</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative incidence rate of portal hypertensive complications among HBeAg-positive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of HCC among HBeAg-negative patients</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative incidence rate of HCC among HBeAg-negative patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause-mortality among HBeAg-negative patients</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>All cause-mortality among HBeAg-negative patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of liver transplantation among HBeAg-negative patients</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative incidence rate of liver transplantation among HBeAg-negative patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of liver decompensation among HBeAg-negative patients</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative incidence rate of liver decompensation among HBeAg-negative patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of portal hypertensive complications among HBeAg-negative patients</measure>
    <time_frame>At year 1, 2, 3 and 4</time_frame>
    <description>Cumulative incidence rate of portal hypertensive complications among HBeAg-negative patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">780</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A (TAF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>390 subjects administered Tenofovir Alafenamide 25 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B (Best supportive care)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>390 subjects received best supportive care
During treatment period, among treatment arm B, subjects who are indicated for antiviral treatment by AASLD 2018 Guidelines of CHB (ALT 70≥ for male, 50≥ for female) will be treated with Tenofovir Alafenamide .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Alafenamide</intervention_name>
    <description>Tenofovir Alafenamide 25mg, Tablet, Oral, Daily</description>
    <arm_group_label>Treatment Arm A (TAF)</arm_group_label>
    <other_name>Vemlidy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients must meet all of the following criteria to be eligible to
        participate in the study

          1. Patient must have the ability to understand and sign a written informed consent form;
             consent must be obtained prior to initiation of study procedures

          2. Male or female, 40 to 80 years of age

          3. Positive for HBsAg or HBV DNA for at least 6 months or more

          4. HBeAg positive or negative

          5. No evidence of liver cirrhosis (platelet count ≥100,000/mm3)

          6. serum HBV DNA ≥ 4 log10 IU/mL and ≤ 8 log10 IU/mL

          7. Serum ALT level ≤70 if male, ≤50 if female

          8. Estimated creatinine clearance ≥ 30 ml/min based on serum creatinine as measured at
             the screening evaluation

          9. Patient is willing and able to comply with all study requirements

        Exclusion Criteria: Patients who meet any of the following exclusion criteria are not to be
        enrolled in this study

          1. Co-infection with HCV, HDV, HIV (Confirmed by nucleic acid tests)

          2. Abusing alcohol (more than 60 g/day) or illicit drugs

          3. Patients with history of hepatic decompensation (e.g., ascites, encephalopathy or
             variceal hemorrhage)

          4. Evidence of cirrhosis, including any of follows:

        1) Platelet count &lt;100,000/mm3 2) Esophagogastric varices on endoscopy 3) Evidence of
        clinically significant portal hypertension

        5. Received interferon or other immunomodulatory treatment for HBV infection in the 12
        months before screening for this study

        6. Medical condition that requires concurrent use of systemic corticosteroid or other
        immunosuppressive agents

        7. Received solid organ or bone marrow transplant

        8. Known hypersensitivity to study drugs, metabolites, or formulation excipients

        9. Any other clinical condition or prior therapy that, in the opinion of the Investigator,
        would make the patient unsuitable for the study or unable to comply with dosing
        requirements

        10. Use of investigational agents within 6 months of screening, unless allowed by the
        Sponsor or Investigator

        11. Significant renal, cardiovascular, pulmonary, or neurological disease in the opinion of
        the Investigator

        12. Any malignant tumor in the preceding five years. However, a history of treated
        malignancy (other than HCC) is allowable if the patient's malignancy has been in complete
        remission, off chemotherapy and without additional surgical intervention, during the
        preceding three years

        13. Pregnant or breastfeeding or willing to be pregnant

        14. Participating in other clinical trials to administer medication. However, it is
        possible to participate if it is not an antiviral agent or immunosuppressant related
        clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Suk Lim, M.D, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Suk Lim, M.D, Ph D</last_name>
    <phone>+82-2-3010-5933</phone>
    <email>limys@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Young-Suk Lim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800.</citation>
    <PMID>29405329</PMID>
  </reference>
  <reference>
    <citation>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.</citation>
    <PMID>28427875</PMID>
  </reference>
  <reference>
    <citation>Tseng TC, Kao JH. Treating Immune-tolerant Hepatitis B. J Viral Hepat. 2015 Feb;22(2):77-84. doi: 10.1111/jvh.12370. Epub 2014 Nov 25. Review.</citation>
    <PMID>25424771</PMID>
  </reference>
  <reference>
    <citation>Andreani T, Serfaty L, Mohand D, Dernaika S, Wendum D, Chazouillères O, Poupon R. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol. 2007 May;5(5):636-41. Epub 2007 Apr 11.</citation>
    <PMID>17428739</PMID>
  </reference>
  <reference>
    <citation>Hui CK, Leung N, Yuen ST, Zhang HY, Leung KW, Lu L, Cheung SK, Wong WM, Lau GK; Hong Kong Liver Fibrosis Study Group. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007 Aug;46(2):395-401.</citation>
    <PMID>17628874</PMID>
  </reference>
  <reference>
    <citation>Kennedy PTF, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, Naik S, Foster GR, Bertoletti A. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology. 2012 Sep;143(3):637-645. doi: 10.1053/j.gastro.2012.06.009. Epub 2012 Jun 15.</citation>
    <PMID>22710188</PMID>
  </reference>
  <reference>
    <citation>Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007 Dec;47(6):760-7. Epub 2007 Sep 24.</citation>
    <PMID>17928090</PMID>
  </reference>
  <reference>
    <citation>Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, Chauhan R, Bose S. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008 May;134(5):1376-84. doi: 10.1053/j.gastro.2008.02.075. Epub 2008 Feb 29.</citation>
    <PMID>18471514</PMID>
  </reference>
  <reference>
    <citation>Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, Lee HC, Lee YS. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018 May;67(5):945-952. doi: 10.1136/gutjnl-2017-314904. Epub 2017 Oct 21.</citation>
    <PMID>29055908</PMID>
  </reference>
  <reference>
    <citation>Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006 Jan 4;295(1):65-73.</citation>
    <PMID>16391218</PMID>
  </reference>
  <reference>
    <citation>Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006 Mar;130(3):678-86.</citation>
    <PMID>16530509</PMID>
  </reference>
  <reference>
    <citation>Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011 Mar;53(3):726-36. doi: 10.1002/hep.24105. Epub 2011 Feb 11. Review.</citation>
    <PMID>21319189</PMID>
  </reference>
  <reference>
    <citation>Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006 Jun;43(6):1317-25.</citation>
    <PMID>16729309</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 22, 2018</study_first_submitted>
  <study_first_submitted_qc>November 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2018</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Suk Lim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

